Innovent Biologics

Home
China
Suzhou
Innovent Biologics

To empower patients worldwide with affordable, high-quality biopharmaceuticals Innovent has launched 17 products in the market.

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

14/04/2026

Results from the Phase 3 CLEAR-1 trial of picankibart (IBI112), an anti–IL-23p19 monoclonal antibody, have been published in the Journal of the American Academy of Dermatology.

The study achieved all primary and key secondary endpoints in moderate-to-severe plaque psoriasis, with robust responses at Week 16 and durable efficacy through one year, alongside a favorable safety profile.

Picankibart is a monoclonal antibody developed by Innovent Biologics that targets the IL-23p19 subunit, inhibiting IL-23–mediated signaling. It is approved in China for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Ongoing and completed studies across psoriasis and other autoimmune indications, including ulcerative colitis, continue to evaluate its broader clinical potential.

These findings add to the evolving landscape of IL-23–targeted therapies and highlight ongoing efforts to improve long-term treatment options for patients living with psoriasis.

13/04/2026

At the Immune Resetting: B-Cell Mediated & Beyond Summit 2026 in Boston, Innovent Biologics presented preclinical data on IBI3055, a CD19/BCMA/CD3 tri-specific T cell engager for autoimmune diseases.

IBI3055 aims to balance potent immune cell depletion with a favorable safety profile. Preclinical studies demonstrated effective elimination of CD19- or BCMA-positive cells across expression levels and significant reductions in immunoglobulin levels in multiple in vivo models.

These findings highlight the potential of tri-specific T cell engager approaches to more precisely target the immune mechanisms underlying autoimmune diseases. Continued research may help advance new treatments designed to reset the immune system and potentially provide longer-lasting relief for patients.https://www.prnewswire.com/news-releases/immune-resetting-b-cell-mediated--beyond-summit-2026-oral-presentation-innovent-biologics-announces-pre-clinical-results-of-ibi3055-a-tri-specific-t-cell-engager-targeting-autoimmune-diseases-302738492.html

07/04/2026

On World Health Day, we stand with science and the global community working to turn discovery into better health for patients everywhere.

At Innovent Biologics, from advancing clinical research in oncology and metabolic disease to collaborating with healthcare partners to bring innovative therapies onto China's National Reimbursement Drug List, our teams work across research, clinical development, and healthcare systems to translate scientific insight into treatments that reach patients who need them. These efforts support China's Healthy China 2030 initiative, which aims to strengthen prevention, expand access to care, and build a healthier society through science and innovation.

We see the same principles in our work globally. Focusing on prevention, building trust in evidence-based health guidance, and making sure patients can access effective care. Whether through clinical trials in China, collaborations in immuno-oncology or metabolic disease, or sharing knowledge with international partners, our efforts connect local impact with the broader goal of improving health worldwide.

This year's theme, "Together for health. Stand with science," highlights how working across disciplines and institutions drives real results. Our teams, from clinical and regulatory to manufacturing and commercial, work hand in hand every day to advance research and deliver therapies that truly improve lives, and to build lasting partnerships that make an impact on patients and healthcare worldwide.

02/04/2026

Ollin Biosciences, a partner of Innovent, has announced final 20-week results from the randomized Phase 1b JADE study evaluating OLN324 (Innovent R&D code IBI324) versus faricimab in patients with Diabetic Macular Edema (DME) and Wet Age Related Macular Degeneration (wAMD).

OLN324 demonstrated faster and greater improvements in key anatomic outcomes in DME, numerically greater vision gains sustained through 20 weeks with fewer retreatments, and faster, more durable reductions in pigment epithelial detachment (PED) thickness in wAMD.

The therapy also showed a favorable safety profile in the study, with no cases of intraocular inflammation, retinal vasculitis, or occlusive retinal vasculitis observed.

Based on these findings, Innovent and Ollin plan to advance OLN324 into global Phase 3 studies in DME and wAMD in 2026, aiming to further evaluate its potential to expand treatment options for patients facing vision-threatening retinal diseases.
https://www.prnewswire.com/news-releases/innovents-partner-ollin-biosciences-announces-final-data-from-randomized-head-to-head-study-of-ibi324-compared-to-faricimab-vabysmo-in-wet-age-related-macular-degeneration-and-diabetic-macular-edema-302727103.html

31/03/2026

We recently published Innovent's 2025 Annual Results, reflecting progress across pipeline advancement, financial performance, and global collaboration.

Behind these results are teams working every day to translate innovation into new treatment options for patients. Watch the video below for a brief look at the milestones that shaped the year.

26/03/2026

Each year, we step back to reflect on our progress and share where we are headed next. Innovent’s 2025 annual results and long-term strategic blueprint highlight continued momentum across commercial growth, pipeline innovation, and global partnerships.

In oncology, cornerstone therapies including TYVYT® (sintilimab), BYVASDA® (bevacizumab), and HALPRYZA® (rituximab) have already benefited millions of patients in China, while five targeted therapies were added to the 2025 National Reimbursement Drug List, further strengthening the company’s innovative oncology portfolio. At the same time, Innovent’s general biomedicine franchise has emerged as a second growth engine, led by SYCUME® (teprotumumab) for thyroid eye disease and mazdutide, the world’s first dual GCG/GLP-1 receptor agonist for obesity and type 2 diabetes, both of which delivered strong momentum in 2025.

2025 also marked an important year for globalization, with multiple core assets advancing toward global Phase 3 studies and collaborations with partners including Takeda, Eli Lilly, and Roche helping accelerate international development. As we move through Innovent’s 15th year, we’re grateful to our colleagues, partners, patients, and the broader community whose support makes this progress possible, and we look forward to continuing this work together in the year ahead.

There’s more in the press release, and we invite you to learn about our latest milestones and our vision for the road ahead.https://en.prnasia.com/releases/global/innovent-announces-2025-annual-results-and-business-updates-526896.shtml

24/03/2026

We're pleased to share that the first participant has been dosed in a Phase 3 clinical study of IBI128 (tigulixostat), a novel non-purine selective xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout. Gout affects millions of people in China and remains an area where new treatment options with strong uric acid-lowering efficacy and good safety are still needed, underscoring the importance of continued innovation in this field. Beyond IBI128, Innovent is advancing a broader pipeline addressing gout and hyperuricemia across different disease stages, including IBI3011 for acute gout flares and mazdutide, a dual GCG/GLP-1 receptor agonist that may offer therapeutic benefits for patients with obesity complicated by hyperuricemia.

https://www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-of-ibi128-tigulixostat-xoi-in-phase-3-clinical-study-302721353.html

24/03/2026

We're delighted to share that Innovent's Phase 3 STAR study of efdamrofusp alfa (IBI302) has met its 52-week primary endpoint in patients with neovascular age-related macular degeneration (nAMD).

As a bispecific fusion protein designed to inhibit both VEGF-driven angiogenesis and complement-mediated inflammation, IBI302 takes an innovative approach to targeting key disease pathways and demonstrated vision improvements comparable to aflibercept in the study. If approved, IBI302 could become the first extended-interval treatment for neovascular age-related macular degeneration in China, representing an important step in Innovent's efforts to expand treatment options for patients. This could potentially reduce the frequency of injections and clinic visits while helping patients maintain durable vision outcomes.https://www.prnewswire.com/news-releases/the-phase-3-registration-star-study-of-efdamrofusp-alfa-ibi302-met-its-primary-endpoint-making-it-the-first-self-developed-extended-interval-treatment-for-namd-in-china-302722243.html

23/03/2026

Join Innovent Biologics for its 2025 Annual Results Conference Call on March 26, during which key business updates and strategic priorities will be presented.

Please register via the link to receive confirmation and access details.

05/03/2026

World Obesity Day is a reminder that behind every statistic is a life shaped by biology, environment, and circumstance, that obesity is not a matter of willpower, but a chronic, relapsing disease requiring sustained, science-based solutions. This year's theme—“8 Billion Reasons to Act”—reflects the scale of the challenge: in 2015, high BMI was associated with 4 million deaths globally, driven by cardiovascular disease, diabetes, chronic kidney disease, and cancer. Obesity is a chronic, relapsing disease, and more than 80% of people living with obesity develop related health complications. One of the most common is fatty liver disease, which often has no obvious symptoms but can improve or even be reversed with evidence-based weight management.

The trajectory often begins early. In China, the combined rate of overweight and obesity among children aged 7-18 has risen from 1.2% in 1985 to 23.4% in 2019, underscoring an urgent and persistent unmet need. Globally, nearly half of the world's population is projected to be living with overweight or obesity by 2035, making prevention, early intervention, and equitable access to care more urgent than ever.

Addressing obesity and its cardiometabolic consequences aligns closely with Innovent's broader mission to expand access to high-quality biologics and treatment support for patients facing serious unmet medical needs, including through our cardiovascular and metabolic disease research efforts. On this World Obesity Day, we stand with the global health community in advancing understanding over stigma, science over simplification, and supporting evidence-based care that can change long-term outcomes.

$We’re pleased to share that Jaypirca (pirtobrutinib) has been approved in China for adults with relapsed or refractory C...$

02/03/2026

We’re pleased to share that Jaypirca (pirtobrutinib) has been approved in China for adults with relapsed or refractory CLL/SLL after at least one prior line of therapy, including a BTK inhibitor. This expands options for patients who progress on covalent BTK agents.

Jaypirca is a highly selective, non-covalent (reversible) BTK inhibitor. It is designed to sustain BTK pathway inhibition, even after prior treatment with agents such as ibrutinib, acalabrutinib, or zanubrutinib. Its approval is supported by results from the BRUIN CLL-321 study.

This decision by the NMPA marks more than a regulatory step forward. It represents meaningful progress for patients in China who have had limited options after BTK therapy and underscores continued efforts to bring innovative hematology treatments to those who need them most.https://www.prnewswire.com/news-releases/jaypirca-pirtobrutinib-approved-in-china-for-the-treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-302699561.html

13/02/2026

Innovent has successfully dosed the first participant in the pivotal Phase 3 HeriCare-Breast01 study evaluating IBI354, a novel HER2 ADC, as a first-line treatment for unresectable locally advanced or metastatic HER2-positive breast cancer.

With two global Phase 3 trials underway, IBI354 represents a next-generation antibody–drug conjugate designed for high potency and low toxicity, aiming to further advance the standard of care. We’re encouraged to see this study move forward and hopeful it will help bring another meaningful option to patients facing HER2-positive disease.https://www.prnewswire.com/news-releases/innovent-dosed-first-participant-in-phase-3-clinical-study-of-ibi354-novel-her2-adc-for-first-line-treatment-of-her2-positive-breast-cancer-302686402.html

Address

Suzhou
215028

Telephone

+8651269566088

Website

https://www.innoventbio.com/

Alerts

Be the first to know and let us send you an email when Innovent Biologics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Innovent Biologics:

Shortcuts

Want your practice to be the top-listed Clinic in Suzhou?

Innovent Biologics

14/04/2026

13/04/2026

07/04/2026

02/04/2026

31/03/2026

26/03/2026

24/03/2026

24/03/2026

23/03/2026

05/03/2026

02/03/2026

13/02/2026

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category